UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case

Munich division asks pharma company for clarity on territorial scope | Sanofi took battle with four generic makers over Jevtana to UPC.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Unified Patent Court

IP Federation warns against ‘blanket ban’ on in-house counsel at UPC

21 January 2025 UK trade association weighs in on Microsoft UPC appeal which deals with issue of representation | Former CIPA head says court should not “divide” European patent profession | SMEs could be forced to opt out patents due to counsel costs.

Biotechnology

Sanofi signs global rights deal to develop rare cancer therapy

13 September 2024 Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

Unified Patent Court

Does the UPC offer a fresh take on patent validity?

5 September 2024 A distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case

More on this story

Editor's picks

Editor's picks

More features